Encompass Design India Ltd. IPO Allotment Status: Check Overall Subscription & Steps to Verify Status 

The allotment for the Encompass Design India Ltd. or ScaleSauce IPO is expected to be finalised today, i.e., December 10, 2025. The IPO opened for subscriptions on December 05, 2025, and closed yesterday, December 09, 2025. The IPO will list on NSE SME, with a tentative listing date of December 12, 2025. It is a book build issue of ₹40.21 crores, with 0.38 crore shares being freshly issued for the IPO. 

Check the Encompass Design India Ltd. IPO Allotment Status on NSE, BSE and the registrar’s website. 

Procedure to Check Encompass Design India Ltd. IPO Allotment Status Online On NSE

• Visit the NSE’s IPO allotment verification status page here. 
• Select “Equity & SME IPO bid details”.
• In Select Symbol, select “Encompass Design India Ltd”.
• Enter your PAN No. and application No. 
• Click “Submit”.

Procedure to Check Encompass Design India Ltd. IPO Allotment Status on MUFG Intime India Pvt. Ltd. (Registrar to the issue)

• Click here to visit MUFG Intime’s application status page. 
• Under “Please select company”, select “Encompass Design India Ltd”.
• Enter any of the following details. 
• PAN
• App. No.
• DP/Client ID  
• Account No / IFSC
• Click “Submit”.

Encompass Design India Ltd. IPO Details

The Encompass Design India Ltd. IPO is a book build issue of ₹40.21 crores, comprising an entirely fresh issue of 0.38 crore shares.

The price band for the IPO has been set at ₹101.00 to ₹107.00 per share, while the lot size is 1,200 per application.

Individual/retail investors need to invest at least ₹2,56,800.00 to get 2,400 shares at the upper price. HNIs have to invest at least in 3 lots or 3,600 shares, aggregating to ₹3,85,200. 

The booking running lead manager for the issue is 3Dimension Capital Services Ltd. At the same time, the registrar is MUFG Intime India Pvt. Ltd., and the Market Maker of the company is Alacrity Securities Ltd.

Encompass Design India Ltd. IPO Overall Subscription Status

Encompass Design India Ltd. saw an overall subscription of 2.19 times as per the NSE data as of December 10, 2025, end of day.

 The public issue was subscribed:

• 1.69 times by Retail Individual Investors (RIIs)
• 4.60 times by Non-Institutional Investors (NIIs)
• 1.25 times by Qualified Institutional Buyers (QIBs)

Explore other Upcoming IPOs on BSE and NSE.

Utilisation of Proceeds

The company plans to utilise the net proceeds from the fresh issue towards:

• ₹11.49 crores- funding capital expenditure requirements (buying an office, refurbishment, interior work, etc.)
• ₹7.29 crores- meeting the company’s working capital needs
• ₹11 crores- repayment or prepayment of certain company borrowings

Check out newly Listed IPOs on BSE and NSE.

About Encompass Design India Ltd.

Encompass Design India Ltd. (EDIL) or ScaleSauce develops and scales Indian consumer brands focused on food, home, and living for contemporary urban consumers. It is a diversified consumer brand that manufactures home and lifestyle products, including curtains, comforters, bed sheets, table linens, and pillow covers, as well as food products such as sauces under various brands. It also trades in cotton, fabrics, agro-based products, and other goods. ScaleSauce also provides extensive digital and e-commerce solutions to help various brands scale up across online marketplaces (operational, marketing, and technology support). EDIL serves not only corporate clients but also D2C (direct-to-consumer) brands. 

Financially, the company reported:

• ₹63.24 crore in assets, total income of ₹28.17 crore, and profit after tax (PAT) of ₹5.05 crore as of September 30, 2025. 
• 37% higher revenues and 57% higher PAT (profit after tax) between the financial year ending with March 31, 2025 and March 31, 2024. 
• EBITDA of ₹8.85 crore and net worth of ₹37.62 crore as of September 30, 2025. 
• Reserves and surplus of ₹27.20 crore as of September 30, 2025. 

Disclaimer: This news is solely for educational purposes. The securities/investments quoted here are not recommendatory.

To read the RA disclaimer, please click here.